GREED WATCH: Bristol Myers Squibb Brought In More Than $45 Billion In 2023
https://www.protectourcare.org/greed-watch-bristol-myers-squibb-brought-in-more-than-45-billion-in-2023/
2019年FDA已批準Eliquis仿製藥。 BMY使用各種策略將其專利延長至2026年。為什麽？ 藥品貢獻了其2/3的利潤。 Eliquis是Medicare處方中的NO.1藥物，受益人數最多的會員 (3.5 million)。雖然Medicare花費最多的不是Eliquis，而是兩種癌症藥物，每種藥物隻惠及不到3萬名會員。
Eiquis is at about $600 a month. Many Medicare Advantage plans cover it with only $5 co-pay but pay the full cost of the drug.
2024 Medicar Plan D allowance is 5030. Once over that you enter the donut hole (coverage gap)
At $600 a month, a patient even ONLY needs Eliquis (hardly likely), would go into donut hole by August.
8x600 = 4800.
一旦進入 Donut Hole，患者將承擔25%的藥品費用加上配藥費（由配藥的藥房收取）。
Basically BMY is a 吸血者. It is about time to do something to stop the sleazy tactics big pharma used, i.e. using loophole to extend patent.
